Abstract:Insulin-like growth factors (lGFs) are potent mitogens for breast cancer cells. Although IGF-binding proteins (IGFBPs) are known to regulate access of IGFs to IGF receptors, their precise biological actions are poorly defined. We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,1O-dimethyl-1 ,2-benzanthracene-induced mammary tumors in vivo. In vitro studies showed that growth inhibition of MCF-7 human breast cancer cells induced by ICI was associated with increased transcription of the IGFBP-5 gene, increased IGFBP-5 mRNA abundance, and increased IGFBP-5 protein accumulation in the conditioned medium. Growth stimulation following estradiol exposure was associated with opposite effects. An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis. Furthermore, this antisense oligodeoxynucleotide attenuated both antiestrogeninduced IGFBP-5 accumulation and antiestrogeninduced growth inhibition. These data demonstrate that estradiol down-regulates and ICI up-regulates an autocnne IGFBP-5 growth inhibitory pathway in MCF-7 cells and suggest that IGFBP-5 plays a role in modulation of proliferation of breast cancers by estrogens and antiestrogens. Introduction IGF3-l and IGF-ll are potent mitogens and inhibitors of apoptosis for many normal and neoplastic cell types (1). Both IGF-l and IGF-lI have high affinity for IGFBPs. To date, six IGFBPs have been characterized (reviewed in Ref. 2). These binding proteins are found in many physiological fluids and Received 5/9/96; revised 7/24/96; accepted 8/6/96. The ‘costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to mdicate this fact. 1 This work was supported by grants from the Canadian Breast Cancer Foundation (Grant 6032 to H. H.) and from the Breast Cancer Initiative Program of the National Cancer Institute of Canada (to M. P.). 2 To whom requests for reprints should be addressed. Phone: (514) 3408260, ext. 5263; Fax: (514) 340-7502. 3 The abbreviations used are: IGF, insulin-like growth factor; IGFBP, IGFbinding protein; ICI, ICI 182780; DMBA, 9,10-dimethyl-1 ,2-benzanthracene; SEPF, serum, estrogen, and phenol red free. conditioned media of a wide variety of cell types and modulate IGF bioactivity in a complex manner. Although the IGFBPs are known to influence access of lGFs to their receptors, their precise physiological roles remain unclear, and both stimulatory and inhibitory effects on cellular proliferation have been reported under various experimental conditions (3-7). The human IGFBP-5 gene is divided into four exons which span 33 kb of DNA (8). IGFBP-S was originally purified from rat serum (9), human bone (1 0), and medium conditioned by human osteoblast-like cells (1 1). IGFBP-5 has been shown to potentiate (1 0, 12) or inhibit (5) IGF action under specific experimental conditions. The different effects of IGFBP-5 observed in various experimental systems may be related to differences in posttranslational modification of IGFBP-5 (13) or to differences in extracellular matrix interactions (14). SV4O transformation provides an example of stimulation of proliferation correlated with decreased IGFBP-5 synthesis and increased cellular responsivity to IGFs (1S). Antiestrogens are widely used in breast cancer treatment, and it has been proposed that effects of these drugs on genes involved in regulation of IGF bioactivity may contribute to their antiproliferative activity (16-1 8). For example, the uterotrophic actions of tamoxifen are correlated with upregulation of IGF-l expression and down-regulation of IGFBP-3 expression, whereas the complete antiestrogen ICI (1 9), which causes uterine involution, is associated with opposite effects (20). The first example of stimulation of an autocrine growth inhibitory loop by an antiestrogen concerned tamoxifen stimulation of transforming growth factor 3 secretion (21). More recently, IGFBP-3 has been implicated in antiestrogen action (7). In this report, we describe experiments designed to evaluate the role of IGFBP-5 gene expression in the modulation of proliferation of estrogen receptor-positive breast cancer cells by estradiol and antiestrogens. Resufts Effects of ICI on IGFBP-5 Gene Expression in DMBAinduced Mammary Tumors. A prior study (1 9) described the antineoplastic activity of ICI on DMBA-induced mammary tumors. Fig. 1 illustrates the effect of ICI on the abundance of IGFBP-5 mRNA in this tumor model. Baseline expression of the IGFBP-5 gene in DMBA-induced breast tumors was stimulated approximately 2-3-fold by ICI. This motivated studies of the role of IGFBP-S in the regulation of breast cancer cell growth in vitro. Effects of Estradiol and ICI on IGFBP-5 Gene Expression in MCF-7 Breast Cancer Cells. Northern blot analysis revealed significant effects of estradiol and ICI on IGFBP-S mRNA abundance. Densitometric scanning of Northern blots revealed that IGFBP-S mRNA abundance was more than 7-fold higher in controls than in cells exposed to 1 0_b M

Treatment of Murine Breast Cancer Cells with Antisense RNA to the Type I Insulin-Like Growth Factor Receptor Decreases the Level of Plasminogen Activator Transcripts, Inhibits Cell Growth in Vitro, and Reduces Tumorigenesis in Vivo.

Targeting The Urokinase Plasminogen Activator Receptor With A Monoclonal Antibody Impairs The Growth Of Human Colorectal Cancer In The Liver

Treatment of human breast cancer cells with antisense RNA to the type I insulin-like growth factor receptor inhibits cell growth, suppresses tumorigenesis, alters the metastatic potential, and prolongs survival in vivo

Ebag9 Inducing Hyporesponsiveness Of T Cells Promotes Tumor Growth And Metastasis In 4t1 Murine Mammary Carcinoma

Constitutively active type I insulin-like growth factor receptor causes transformation and xenograft growth of immortalized mammary epithelial cells and is accompanied by an epithelial-to-mesenchymal transition mediated by NF-kappaB and snail.

Developmental Stage Determines Estrogen Receptor Alpha Expression and Non-Genomic Mechanisms That Control IGF-1 Signaling and Mammary Proliferation in Mice.

Inhibition of Colon Cancer Metastasis by a 3'- End Antisense Urokinase Receptor Mrna in a Nude Mouse Model.

[Shrna-Mediated Insulin-Like Growth Factor I Receptor Gene Silencing Inhibits Cell Proliferation, Induces Cell Apoptosis, and Suppresses Tumor Growth in Non-Small Cell Lung Cancer: in Vitro and in Vivo Experiments].

The inhibited effect of RNA interference technology silencing IGF-1R on endometrial carcinoma proliferation and tumorigenesis in nude mice

Paracrine Overexpression of Insulin-Like Growth Factor-1 Enhances Mammary Tumorigenesis in Vivo

Soluble M6P/IGF2R released by TACE controls angiogenesis via blocking plasminogen activation

Rna Interference Affects Tumorigenicity and Expression of Insulin-Like Growth Factor-1, Insulin-Like Growth Factor-1 Receptor, and Basic Fibroblast Growth Factor-2 in Rat C6 Glioma Cells

Suppression of Type 1 Insulin-Like Growth Factor Receptor Expression by Small Interfering Rna Inhibits A549 Human Lung Cancer Cell Invasion in Vitro and Metastasis in Xenograft Nude Mice

Poly(I:C) transfection induces a pro-inflammatory cascade in murine mammary carcinoma and fibrosarcoma cells

Down-regulation of IGF-1R Expression Inhibits Growth and Enhances Chemosensitivity of Endometrial Carcinoma in Vitro

P4-02-05: the Regulation of Artemin Signalling by IGF-1 in Mammary Carcinoma Cells.

A Role for Insulin-like Growth Factor Binding Protein 5 in the Antiproliferative Action of the Antiestrogen ICI 1827801

Abstract P2-26-13: Gene deletion of insulin receptor in MCF-7L breast cancer cells by CRISPR gene editing

Estrogen receptor α (ERα) regulates insulin-like growth factor-1 (IGF-1) action in mammary glands in vivo

Down-Regulation of Igf-Ir Using Small, Interfering, Hairpin Rna (sirna) Inhibits Growth of Human Lung Cancer Cell Line A549 in Vitro and in Nude Mice

Effect of antisense gene of type Ⅱ insulin-like growth factor receptor on malignant phenotype of human hepatoma cells in vitro